Table 2.
Baseline descriptive information on the study samples.
| Patients (N = 129) | Controls (N = 130) | p-Valuea | |
|---|---|---|---|
| Age, years, Md (Q1, Q3) | 25.0 (22.0, 30.1) | 25.0 (22.5, 31.0) | 0.28 |
| Male/female, n | 82/47 | 59/71 | 0.003 |
| Years of education, Md (Q1, Q3) | 13 (12, 15.5) | 15.5 (13, 17) | <0.0001 |
| BMI, Md (Q1, Q3) | 23.0 (21.3, 27.1) | 24.0 (21.8, 26.9) | 0.24 |
| Current smoking, n (%) | 28 (27.7 %)b | 11 (9.1 %)c | 0.0003 |
| Cannabis use (past 12 months), n (%) | 29 (26.1 %)d | 25 (19.8 %)e | 0.25 |
| Antipsychotics used at baseline: | |||
| Olanzapine, n (%) | 45 (34.9 %) | 0 | |
| Risperidone, n (%) | 45 (34.9 %) | 0 | |
| Quetiapine, n (%) | 25 (19.4 %) | 0 | |
| Aripiprazole, n (%) | 7 (5.4 %) | 0 | |
| Ziprasidone, n (%) | 1 (0.8 %) | 0 | |
| Sertindole, n (%) | 1 (0.8 %) | 0 | |
| Paliperidone, n (%) | 2 (1.6 %) | 0 | |
| Haloperidol, n (%) | 4 (3.1 %) | 0 | |
| Perphenazine, n (%) | 3 (2.3 %) | 0 | |
| Chlorpromazine, n (%) | 2 (1.6 %) | 0 | |
| No antipsychotic, n (%) | 16 (12.4 %) | 130 (100 %) | |
aχ2 test used for categorical variables, Wilcoxon two-sample test with t approximation for continuous variables.
bInformation missing on 28 participants.
cInformation missing on 9 participants.
dInformation missing on 18 participants.
eInformation missing on 4 participants.
Md median, Q1 first quartile, Q3 third quartile.
Bold values indicate p < 0.05.